- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Statin initiation in high risk patients not to be delayed due to cataract risk: JAHA
Denmark: A recent study, published in the Journal of the American Heart Association found that HMG-CoA reductase inhibition (the target of statins) is associated with a high risk of cataract development.
The authors, however, suggest that the beneficial effects of statins are unequivocal, "the reported link with lens opacities should not prevent statin initiation in high‐risk adults, but should be disclosed to the patient, particularly when indicated for primary prevention." Jonas Ghouse, University of Copenhagen, Denmark, and colleagues wrote in their study.
There have been increasing concerns regarding the potential cataractogenic effects of statin treatment. Dr. Ghouse and the team aimed to investigate whether common and rare genetic variants in HMGCR are associated with cataract risk, to gauge the likely long‐term effects of statin treatment on lenticular opacities.
For this purpose, the researchers used genotyping data and exome sequencing data of unrelated European individuals in the UK Biobank for testing the association between genetically proxied inhibition of HMGCR and cataract risk. First, they constructed an HMGCR genetic score consisting of 5 common variants weighted by their association with low‐density lipoprotein cholesterol. Second, they analyzed exome sequencing data to identify carriers of predicted loss‐of‐function mutations in HMGCR. Then, common and rare variants were tested for association with cataracts and cataract surgery.
Based on the study, the researchers reported the following findings:
- In an analysis of more than 402 000 individuals, a 38.7 mg/dL (1 mmol/L) reduction in low‐density lipoprotein C by the HMGCR genetic score was associated with a higher risk for cataracts (odds ratio, 1.14) and cataract surgery (odds ratio, 1.25).
- Among 169 172 individuals with HMGCR sequencing data, we identified 32 participants (0.02%), who carried a rare HMGCR predicted loss‐of‐function variant.
- Compared with noncarriers, heterozygous carriers of HMGCR predicted loss‐of‐function had a higher risk of developing cataracts (odds ratio, 4.54) and cataract surgery (odds ratio, 5.27).
- In exploratory analyses, we found no significant association between genetically proxied inhibition of PCSK9, NPC1L1, or circulating low‐density lipoprotein cholesterol levels and cataract risk.
"We found that genetically proxied inhibition of the HMGCR gene mimicking long‐term statin treatment was associated with a higher risk of cataracts," the researchers concluded. "Clinical trials with longer follow-ups are needed to confirm these findings."
"A closer clinical follow‐up may be warranted in younger patients with familial hypercholesterolemia, who are subject to almost life‐long statin therapy often initiated in childhood or early adolescence," the researchers wrote their study.
Reference:
The study titled, "Association of Common and Rare Genetic Variation in the 3‐Hydroxy‐3‐Methylglutaryl Coenzyme A Reductase Gene and Cataract Risk," was published in the Journal of the American Heart Association.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751